| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23029 |
| Drug |
Olaparib |
| Brand |
Lynparza® |
| Indication |
Olaparib in combination with abiraterone and prednisone or prednisolone is indicated for the treatment of adult patients with mCRPC in whom chemotherapy in not clinically indicated |
| Rapid review commissioned |
31/05/2023 |
| Rapid review completed |
13/06/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with abiraterone and prednisone or prednisolone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/06/2023 |
| Pre-submission consultation with Applicant |
09/08/2023 |
| Full submission received from Applicant |
31/01/2024 |
| Preliminary review sent to Applicant |
21/11/2024 |
| NCPE assessment re-commenced |
19/12/2024 |
| Follow-up to preliminary review sent to Applicant |
13/02/2025 |
| NCPE assessment re-commenced |
11/03/2025 |
| Factual accuracy sent to Applicant |
28/04/2025 |
| NCPE assessment re-commenced |
02/05/2025 |
